🇨🇳 Starna Therapeutics raises nearly $40M in Series B Tencent and Source Code Capital co‑led the round. Just six months after its $44M Series B, Starna secures another investment to accelerate its in vivo CAR‑T pipeline, build extrahepatic delivery platforms (lung, gut, CNS), and further strengthen its mRNA therapeutics strategy.

$PRME New breakthrough in in vivo delivery for Prime Editing: SORT LNPs deliver Cas9 mRNA to efficiently edit skeletal muscle in a dystrophy model . 40% restoration of Telethonin without viruses and with low immunogenicity! Huge potential for muscular dystrophies. It seems that little by little new approaches are emerging that could reduce the biggest risk of the platform. Source: cell.com/molecular-therapy-f…

The transition from AAV-mediated OSK to transient mRNA-based OSKM stoichiometry is the critical inflection point for Retro. While Life Biosciences targets localized AAV2 delivery for NAION, Retro's $1B bet on systemic rejuvenation hinges on resolving LNP-mediated biodistribution bottlenecks to extra-hepatic tissues. If the mRNA half-life isn't optimized for specific PD endpoints in CD8 T-cell exhaustion or myofiber proteostasis, the sarcopenia signal will be lost in the noise of off-target hepatic uptake. The real regulatory moat isn't just the 'aging as disease' debate; it is establishing a quantitative MoA that correlates partial reprogramming with functional Phase 3 outcomes before the capital burn forces a pivot to niche orphan indications.